Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency

Blood

Volumn 113, Issue 3, 2009, Pages 723-725

  Ajzner, Éva ^a   Schlammadinger, Ágota ^b   Kerényi, Adrienne ^a   Bereczky, Zsuzsanna ^a   Katona, Éva ^a   Haramura, Gizella ^a   Boda, Zoltán ^b   Muszbek, László ^a,b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPITOPE; FIBROGAMMIN P; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID; UNCLASSIFIED DRUG; AUTOANTIGEN; BLOOD CLOTTING FACTOR 13B; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; ARTICLE; BETA CHAIN; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CASE REPORT; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; PLASMAPHERESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; CHRONIC KIDNEY FAILURE; IMMUNOLOGY; RENAL REPLACEMENT THERAPY;

ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOANTIGENS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIII; FACTOR XIII DEFICIENCY; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMAPHERESIS; RENAL DIALYSIS;

EID: 60249088087     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-179333     Document Type: Article

References (25)

1. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94:271-305.
2. Greenberg CS, Sane DC, Lai T. Factor XIII and fibrin stabilization. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott Williams and Wilkins. 2006;317-334.
3. Muszbek L, Bagoly Z, Bereczky Z, KatonaE' . The Involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardivasc Hematol Agents Med Chem. 2008;6:190-205.
4. Lorand L, Losowsky MS, Miloszweski KJA. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb. 1980;5:245-90.
5. Girolami A, Burul A, Fabris F, Cappellato G, Betterle C. Studies on factor XIII antigen in congenital factor XIII deficiency: a tentative classification of the disease in two groups. Folia Haematol. 1978;105:131-141.
6. Capellato MG, Lazzaro AR, Marafioti F, Polato G, Girolami A. A new family with congenital factor XIII deficiency showing a deficit of both subunit A and B: type I factor XIII deficiency. Haematologia (Budap). 1987;20:179-187.
7. Saito M, Asakura H, Yoshida T, et al. A familial factor XIII subunit B deficiency. Br J Haematol. 1990;74:290-294.
8. Koseki S, Souri M, Koga S, et al. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood. 2001;97:2667-2672.
9. Izumi T, Hashiguchi T, Castaman G, et al. Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second sushi domain. Blood. 1996;87:2769-2774.
10. Lorand L, Maldonado N, Fradera J, Atencio AC, Robertson B, Urayama T. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol. 1972;23:17-27.
11. Lopaciuk S, Bykowska K, McDonagh JM, et al. Differences between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest. 1978;61: 1196-1203.
12. Lorand L, Velasco PT, Rinne JR, Amare M, Miller LK, Zucker ML. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci U S A. 1988;85: 232-236.
13. Fukue H, Anderson K, McPhedran P, Clyne L, McDonagh J. A unique factor XIII inhibitor to fibrin- binding site on factor XIIIA. Blood. 1992;79: 65-74.
14. Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol. 1995;48:34-39.
15. Lorand L, Velasco PT, Murthy SNP, Lefebvre P, Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood. 1999;93:909-917.
16. Ka'rpa' ti L, Penke B, KatonaE' , Balogh I, Va'mosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem. 2000;46:1946-1955.
17. KatonaE' , Haramura G, Ka'rpa' ti L, Fachet J, Muszbek L. A simple quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost. 2000;83:268-273.
18. KatonaE' , AjznerE' , To'th K, Ka'rpa' ti L, Muszbek L. Enzyme linked immunosorbent assay (ELISA) for he determination of blood coagulation factor XIII A-subunit in plasma and in cell lysate. J Immunol Methods. 2001;258:127-135.
19. O'Shannessy DJ. Antibodies biotinylated via sugar moieties. Methods Enzymol. 1990;184:162-166.
20. Lorand L, Credo RB, Janus TG. Factor XIII (fibrin stabilizing factor). Methods Enzymol. 1981;80: 333-341.
21. Polga' r J, Hidasi V, Muszbek L. Non-proteolytic activation of cellular protransglutaminase (placental macrophage factor XIII). Biochem J. 1990; 267:557-560.
22. Chung SI, Lewis MS, Folk JE. Relationship of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures. J Biol Chem. 1974;249:940-950.
23. Fear DJ, Miloszewski KJA, Losowsky MS. The half life of factor XIII in the management of inherited deficiency. Thromb Haemost. 1983;49:102-105.
24. Rodeghiero F, Tosetto A, Di Bona E, Castaman G. Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency.Am J Hematol. 1991;36:30-34.
25. Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomized study. Thromb Haemost. 1995;74:622-625.